LCL161(口服SMAC模拟物)治疗骨髓纤维化的2期临床试验最终结果
这项单中心研究者发起的2期试验评估了口服SMAC模拟物LCL161(起始剂量每周1500 mg)在中高危骨髓纤维化患者中的疗效。患者中66%既往接受过≥2种治疗,中位基线血小板计数52×10^3/μL,28%携带ASXL1突变。结果显示30%患者达到IWG-MRT 2013客观缓解,6例应答者出现贫血临床改善(4例血红蛋白应答,2例脱离输血),中位总生存期34个月(范围2.2-60.1+个月),所有应答者均观察到cIAPs降低。
要点
- LCL161在中高危骨髓纤维化中达到30%的IWG-MRT 2013客观缓解率。
- 6例应答者出现贫血改善:4例血红蛋白应答,2例脱离输血。
- 常见毒性为恶心/呕吐(64%,多为1/2级)、疲乏(46%)、头晕/眩晕(30%)。
核心结论
- SMAC模拟物LCL161在中高危骨髓纤维化患者中显示出客观缓解和贫血改善,可能成为血小板减少或JAK抑制剂失败患者的选择。
研究设计与样本
- 单中心、研究者发起的2期临床试验,口服LCL161起始剂量每周1500 mg,纳入中高危骨髓纤维化患者。
主要发现
- 66%患者既往接受≥2种治疗,中位基线血小板计数52×10^3/μL,28%携带ASXL1突变。
- 30%患者达到IWG-MRT 2013客观缓解。
- 6例应答者出现贫血临床改善:4例血红蛋白应答,2例脱离输血。
- 中位总生存期34个月(范围2.2-60.1+个月)。
- 所有应答者均观察到cIAPs降低。
关键数值与推荐
- 客观缓解率30%,依据IWG-MRT 2013标准。
- 中位总生存期34个月(范围2.2-60.1+个月)。
- 最常见毒性:恶心/呕吐64%(多为1/2级)、疲乏46%、头晕/眩晕30%。
- 4例3/4级不良事件:2例晕厥,1例恶心/呕吐,1例皮疹/瘙痒。
- 研究期间2例死亡,均与试验药物无关。
临床怎么用
- 对于血小板减少或既往JAK抑制剂治疗失败的老年骨髓纤维化患者,LCL161可能作为一种治疗选择。
局限性
- 单中心、研究者发起的小样本2期试验,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcomes in patients with high-risk and treatment-resistant myelofibrosis (MF) post-JAK inhibitor therapy remain poor, with no approved drug therapies beyond the JAK inhibitor class. In certain clinical situations, such as severe thrombocytopenia, administration of most JAK inhibitors are contraindicated. Thus, there is an unmet medical need for the development of novel agents for patients with MF. SMAC mimetics [or inhibitor of apoptosis (IAP) antagonists] induce apoptosis in cancer cells. Because these agents are hypothesized to have increased activity in a tumor necrosis factor-α cytokine-rich microenvironment, as is the case with MF, we conducted a single-center, investigator-initiated phase 2 clinical trial, with a monovalent SMAC mimetic LCL161 (oral, starting dose, 1500 mg per week) in patients with intermediate to high-risk MF. In an older group, 66% with ≥2 prior therapies and a median baseline platelet count of 52 × 103/μL and 28% with ASXL1 mutations, we observed a 30% objective response by Revised International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) 2013 criteria. Notably, 6 responding patients achieved clinical improvement of anemia: 4, hemoglobin response; 2, transfusion independence. Median OS was 34 months (range, 2.2-60.1+). Reductions of cIAPs were observed in all responders. The most common toxicity was nausea/vomiting (N/V) in 64% (mostly grade 1/2); fatigue in 46%; and dizziness/vertigo in 30%. There were 4 grade 3/4 adverse events (2, syncope; 1, N/V; 1, skin eruption/pruritis). There were 2 deaths during the study period, both unrelated to the study drug. SMAC mimetics may represent an option for older patients with thrombocytopenia or for those in whom prior JAK inhibitors has failed. This trial was registered at www.clinicaltrials.gov as #NCT02098161.
引用
- Pemmaraju N, Carter BZ, Bose P, et al. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 2021. PMID: 34424319. doi:10.1182/bloodadvances.2020003829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。